Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations.
Jeffrey AhnMisako NagasakaPublished in: Cancer management and research (2023)
In metastatic non-small cell lung cancer (NSCLC), tumors that do not harbor driver mutations in EGFR or gene fusions in ALK and ROS, PD-1 and PD-L1 inhibitors have become a cornerstone in first line treatment, either as monotherapy or in combination with chemotherapy. This paper reviews cemiplimab-rwlc, the third PD-1/L1 inhibitor to be approved in the setting for first line treatment in NSCLC, as monotherapy or in combination therapy with chemotherapy, to provide a perspective on the subtle differences in patient population for the cemiplimab studies and consideration of its primary and subgroup results in the context of first line therapies for NSCLC.
Keyphrases
- combination therapy
- small cell lung cancer
- advanced non small cell lung cancer
- epidermal growth factor receptor
- brain metastases
- case report
- locally advanced
- squamous cell carcinoma
- genome wide
- cell death
- clinical trial
- systematic review
- dna damage
- gene expression
- randomized controlled trial
- dna methylation
- transcription factor
- oxidative stress
- case control
- drug administration